Rho kinase inhibition: a new approach for treating diabetic nephropathy?
Bach
Leon A
LA
Department of Medicine, Monash University, Melbourne, Victoria, Australia. leon.bach@med.monash.edu.au
D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D000577:Amides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D003928:Diabetic Nephropathies / Q000188:drug therapy*; D006801:Humans; D051379:Mice; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D011725:Pyridines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D054460:rho-Associated Kinases / Q000037:antagonists & inhibitors*
D000577:Amides; D047428:Protein Kinase Inhibitors; D011725:Pyridines; C108830:Y 27632; D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D054460:rho-Associated Kinases; C049347:fasudil